Alyeska Investment Group
KLRS

Alyeska Investment Group’s Kalaris Therapeutics KLRS Stock Holding History

Alyeska Investment Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.27M Buy
572,687
+169,136
+42% +$1.5M 0.01% 519
2025
Q4 		$3.4M Buy
+403,551
New +$2.58M 0.01% 488
2023
Q3 		– Sell
-17,391
Closed -$1.36M – 648
2023
Q2 		$1.36M Buy
+17,391
New +$1.65M 0.01% 434

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group's KLRS Position: Q1 2026 in Review

Alyeska Investment Group increased its Kalaris Therapeutics (KLRS) stake by 42% in Q1 2026, buying an estimated $1.5M and bringing the position to 572,687 shares worth $3.27M. The position accounts for 0.01% of the portfolio, ranked #519.

Alyeska Investment Group first reported a position in KLRS in Q2 2023 and has held it in 3 quarters since. The position peaked at $3.4M in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Alyeska Investment Group held 572,687 shares of Kalaris Therapeutics worth $3.27M as of Q1 2026.
  • Alyeska Investment Group bought 169,136 Kalaris Therapeutics shares in Q1 2026, an estimated $1.5M.
  • Kalaris Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #519 holding.
  • Alyeska Investment Group first reported a position in Kalaris Therapeutics in Q2 2023 and has held it in 3 quarters since.
  • Alyeska Investment Group's Kalaris Therapeutics position peaked at $3.4M in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.